Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 plus F007 in relapsed/refractory DLBCL
CTR20212574Phase 2Terminated
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in diffuse large B-cell lymphoma (DLBCL), sponsored by Shandong New Era Pharmaceutical. Started Oct 2021; status: terminated.
02
Drugs
rulonilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20212574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212574.